[Translation] A clinical study evaluating the safety, pharmacokinetics and efficacy of QX005N in Chinese adolescent subjects with moderate to severe atopic dermatitis

主要研究目的评估QX005N在中重度AD青少年受试者中的安全性和耐受性评估QX005N在中重度AD青少年受试者中的药代动力学（PK）特征次要研究目的评估QX005N在中重度AD青少年受试者中的有效性评估QX005N的免疫原性探索性目的评估QX005N在中重度AD青少年受试者中的药效学（PD）特征

[Translation]

Primary study objectives Evaluate the safety and tolerability of QX005N in adolescent subjects with moderate to severe AD Evaluate the pharmacokinetic (PK) characteristics of QX005N in adolescent subjects with moderate to severe AD Secondary study objectives Evaluate the efficacy of QX005N in adolescent subjects with moderate to severe AD Evaluate the immunogenicity of QX005N Exploratory objectives Evaluate the pharmacodynamic (PD) characteristics of QX005N in adolescent subjects with moderate to severe AD

Start Date06 Jun 2024

Sponsor / Collaborator

Qyuns Therapeutics Co., Ltd.Startup

CTR20241660 / RecruitingPhase 3

一项评价QX005N在治疗结节性痒疹成人受试者中的有效性和安全性的多中心、随机、双盲、安慰剂对照的III期临床研究

[Translation] A multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of QX005N in the treatment of adult subjects with nodular prurigo

主要目的：评估QX005N在PN受试者中对瘙痒缓解的有效性。

[Translation]

Primary objective: To evaluate the effectiveness of QX005N on pruritus relief in subjects with PN.

Start Date22 May 2024

Sponsor / Collaborator

Qyuns Therapeutics Co., Ltd.Startup

ChiCTR2400082755 / RecruitingPhase 1/2IIT

A clinical trial evaluating the safety, pharmacokinetics, and efficacy of QX005N in adolescent patients with moderate to severe atopic dermatitis in China - QX005NA-06

Start Date01 May 2024

Sponsor / Collaborator-

100 Clinical Results associated with QX-005N

100 Translational Medicine associated with QX-005N

100 Patents (Medical) associated with QX-005N

Literatures (Medical) associated with QX-005N

01 Jul 1977·American Journal of Physiology-Endocrinology and Metabolism

Active alkalinization by amphibian gastric fundic mucosa in vitro.

Article

Author: Flemstrom, Gunnar

Gastric fundic mucosae in vitro from four species of frog and Necturus secrete HCO-3 at a steady-state rate of 0.25-0.55 microneq-cm-2-h-1 which corresponds to 5-10% of maximal H+ secretion. Net alkalinization was quantitated in mucosae with spontaneously resting H+ secretion or in mucosae inhibited by histamine H2-receptor antagonists or SNC-. HCO-3 secretion was inhibited by DNP (10(-4) M), CN- (10(-2) M), or anoxia. Acetazolamide inhibited alkalinization at 10(-2) M when added to the nutrient side and at 10(-4) M on the luminal side. Carbachol (10(-4) M) and DBcGMP (10(-4) M) stimulated alkalinization and caused a transient rise in the transmucosal PD; DBcAMP (10(-3) M) was without effect. An almost identical secretion occurred spontaneously in antral mucosae and was insensitive to histamine (10(-5) M). Occurrence in both antral and fundic mucosa suggests that active alkalinization is a property of gastric surface epithelial cells. Gastric alkalinization may protect the luminal surface of the mucosa from the damaging effects of acid and contribute to the continuous removal of H+ ions from gastric contents.

100 Deals associated with QX-005N

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
prurigo nodularis	Phase 3	CN	Qyuns Therapeutics Co., Ltd.Startup	22 May 2024
Dermatitis, Atopic	Phase 3	CN	Qyuns Therapeutics Co., Ltd.Startup	28 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 2	CN	Qyuns Therapeutics Co., Ltd.Startup	03 Mar 2023
Pulmonary Disease, Chronic Obstructive	IND Approval	CN	Qyuns Therapeutics Co., Ltd.Startup	15 Sep 2023
Asthma	IND Approval	CN	Qyuns Therapeutics Co., Ltd.Startup	22 Feb 2022
Chronic Urticaria	IND Approval	CN	Qyuns Therapeutics Co., Ltd.Startup	27 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

QX-005N

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation